Anti-Human CD3 x BCMA (Teclistamab) – Fc Muted™

Anti-Human CD3 x BCMA (Teclistamab) – Fc Muted™

Product No.: C975

- -
- -
Product No.C975
Clone
JNJ-64007957
Target
CD3 x BCMA
Product Type
Biosimilar Recombinant Human Monoclonal Antibody
Alternate Names
CD3ε: T-cell surface antigen T3/Leu-4 epsilon chain, T3E
BCMA: tumor necrosis factor receptor superfamily member 17, CD269
Isotype
Human IgG4κ
Applications
Agonist
,
FA
,
FC

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Human
Host Species
Human
Expression Host
HEK-293 Cells
FC Effector Activity
Muted
Immunogen
BCMA-Fc recombinant protein
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
≤ 1.0 EU/mg as determined by the LAL method
Purity
≥95% by SDS Page
≥95% monomer by analytical SEC
Formulation
This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
State of Matter
Liquid
Product Preparation
Recombinant biosimilar antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Pathogen Testing
To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.
Storage and Handling
Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Regulatory Status
Research Use Only
Country of Origin
USA
Shipping
2 – 8° C Wet Ice
Additional Applications Reported In Literature ?
Agonist,
FA,
FC
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Teclistamab. Teclistamab simultaneously binds CD3ε and B cell maturation antigen (BCMA).
Background
CD3 is an invariant antigen of the T cell TCR (T cell receptor)1. BCMA is a member of the tumor necrosis factor family of receptors that regulates B cell maturation, proliferation, and survival by activating p38/NF-κB and inducing upregulation of antiapoptotic proteins2. BCMA is highly expressed on multiple myeloma (MM) cells and is therefore a target of cancer immunotherapy.

Teclistamab is a humanized IgG4-proline, alanine, alanine (IgG4-PAA) DuoBody CD3xBCMA Bispecific T cell Engager (BiTE) antibody developed for treatment of MM2,3. Teclistamab treatment redirects CD3+ T cells to BCMA-expressing MM cells, leading to the secretion of perforin and certain granzymes from the cytotoxic T cells and ultimately inducing antibody-dependent cell cytotoxicity and tumor cell death of the BCMA-expressing B cells. The process is not specific and MHC I molecules on antigen presenting cells are not involved3. Teclistamab treatment also leads to the secretion of interferon-γ, TNF-α, IL-2, IL-6, IL-8, and IL-102 cytokines are induced2,3. Additionally, activity is increased by the γ-secretase inhibitor LY-4115752.

Teclistamab was generated by immunizing OmniRats (Open Monoclonal Technology) with BCMA-Fc recombinant protein and re-cloning hits on a relatively silent IgG4-PAA scaffold2. A controlled Fab-arm exchange of a BCMA antibody and a CD3 parental antibody derived from SP34 was then performed. The Fc region of Teclistamab contains S228P/L234A/L235A mutations to minimize its immunological effector functions.

Teclistamab has been approved for treatment of MM in patients who demonstrate disease progression despite treatment3.
Antigen Distribution
CD3ε is a T cell surface glycoprotein. BCMA is predominantly expressed on the surface of terminally differentiated B cells and is overexpressed and activated on malignant multiple myeloma B cells (plasmablasts and plasma cells).
Ligand/Receptor
CD3ε: TCR <br> BCMA: TNFSF13B/BLyS/BAFF, TNFSF13/APRIL, TRAF1, TRAF2, TRAF3, TRAF5 and TRAF6
NCBI Gene Bank ID
CD3ε: X03884

BCMA: Z14954
UniProt.org
CD3ε: P07766

BCMA: Q02223
Research Area
Adaptive Immunity
.
Cancer
.
Immuno-Oncology

References & Citations

1 Mariuzza RA, Agnihotri P, Orban J. J Biol Chem. 295(4):914-925. 2020.
2 Pillarisetti K, Powers G, Luistro L, et al. Blood Adv. 4(18):4538-4549. 2020.
3 Kang C. Drugs. 82(16):1613-1619. 2022
4 Usmani SZ, Garfall AL, van de Donk NWCJ, et al. Lancet. 398(10301):665-674. 2021.
5 Moreau P, Garfall AL, van de Donk NWCJ, et al. N Engl J Med. 387(6):495-505. 2022.
6 Glatte B, Wenk K, Grahnert A, et al. Blood Adv. 7(15):3842-3845. 2023.
7 Miao X, Wu LS, Lin SXW, et al. Target Oncol. 18(5):667-684. 2023.
Agonist
FA
Flow Cytometry

Certificate of Analysis

Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.